HeXun Biosciences Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on HeXun Biosciences's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Life Sciences Industry Growth | 5.5% |
| Revenue growth rate | 214.0% |
| Return on equity | 22.6% |
| Net Margin | 52.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How HeXun Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 236 | 124 | 37 | 63 |
| 31 Mar 24 | 183 | 79 | 35 | 58 |
| 31 Dec 23 | 131 | 33 | 33 | 53 |
| 30 Sep 23 | 103 | 13 | 28 | 52 |
| 30 Jun 23 | 75 | -7 | 23 | 51 |
| 31 Mar 23 | 62 | -6 | 19 | 45 |
| 31 Dec 22 | 49 | -5 | 14 | 39 |
Quality Earnings: 6986 has a high level of non-cash earnings.
Growing Profit Margin: 6986 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6986's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: 6986 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6986 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-5.2%).
Return on Equity
High ROE: 6986's Return on Equity (22.6%) is considered high.